MELBOURNE, Australia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has entered into a Product Development and Profit Share Agreement (the “Agreement”), with Melbourne Health (“Melbourne Health”), operator of The Royal Melbourne Hospital and one of Australia’s top public health services with extensive research capabilities. Under the Agreement, Gelteq and Melbourne Healt ...

Core Viewpoint - Gelteq Limited has successfully transitioned from research and development to active commercialization in the U.S. market through its collaboration with Healthy Extracts, marking a significant milestone for the company [2][3]. Company Overview - Gelteq Limited, headquartered in Melbourne, Australia, specializes in developing gel-based oral delivery solutions for various applications, including prescription drugs, nutraceuticals, pet care, and sports nutrition [4]. - The company's proprietary formulation technology addresses challenges in conventional drug delivery, such as taste masking, swallowing difficulties, and precision dosing [4]. Recent Developments - Healthy Extracts has launched products utilizing Gelteq's proprietary gel technology, which are the first to reach Gelteq's U.S. warehousing facility [2]. - The partnership with Healthy Extracts has evolved from initial warehousing and fulfillment arrangements to active sales and distribution, indicating growing momentum for Gelteq's gel delivery system [3]. Market Potential - The development highlights the growth potential of Gelteq's technology in large-scale wellness markets in the U.S. and its capability to meet consumer demand for innovative and clinically-informed products [2]. - The collaboration is expected to pave the way for additional products and partnerships in the U.S. market, enhancing Gelteq's presence and opportunities [3].

Company Overview - Gelteq Limited is a clinical and science-based company specializing in gel-based oral delivery solutions, headquartered in Melbourne, Australia [5] - The company is focused on developing and commercializing gel formulations for prescription drugs, nutraceuticals, pet care, and sports nutrition [5] Product Development - Gelteq plans to commence a preclinical bioequivalence study in September 2025 to evaluate a novel gel-based formulation of a widely used antihistamine for allergy treatment [1] - If preclinical results are successful, the company anticipates advancing to human clinical trials targeting FDA approval via the 505(b)(2) regulatory pathway [2] Market Opportunity - Allergic conditions affect over 50 million people annually in the United States, indicating a significant market for allergy treatments [3] - The global antihistamine market was valued at approximately USD 9 billion in 2023, growing at a 6% CAGR, projected to reach over USD 12 billion by 2028 [3][4] - Demand for antihistamines spans pediatric, adult, and animal health sectors, reflecting diverse applications for these therapies [3] Competitive Advantage - Gelteq's proprietary gel formulations aim to address limitations of traditional tablets and syrups, such as palatability for children, swallowing difficulties for the elderly, and precise dosing needs in veterinary medicine [4] - The innovative gel technology offers advantages in taste masking, ease of administration, and flexible dosing, particularly relevant in pediatric and veterinary care [5]

Core Insights - Gelteq Limited has entered into a memorandum of understanding with IDT Australia to establish a dedicated manufacturing facility for gel-based products targeting global pharmaceutical, nutraceutical, and animal health markets [1][3]. Company Overview - Gelteq is a clinical and science-based company headquartered in Melbourne, Australia, focusing on developing and commercializing white label gel-based delivery solutions across five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition [5]. Partnership Details - The partnership with IDT Australia leverages IDT's 50 years of expertise in pharmaceutical projects and contract manufacturing, including high containment and high potency manufacture of Active Pharmaceutical Ingredients (API) [2][3]. - IDT's capabilities include FDA and TGA approved laboratory testing and clinical packaging, as well as advanced therapies like mRNA and Antibody Drug Conjugates (ADCs) [2]. Strategic Benefits - The collaboration is expected to accelerate the development and scaling of Gelteq's products, enhancing their delivery systems for wellness and therapeutic applications [3]. - Gelteq's proprietary gel technologies are designed to address challenges associated with traditional drug delivery methods, such as difficulty swallowing and dosage control [6]. Manufacturing Requirements - The agreement outlines the need for facilities and equipment tailored for Gelteq products, including compliance with regulatory requirements from APVMA, FDA, and TGA [7]. - The facility will have rapid scale-up capabilities to accommodate growth and integrate additional manufacturing space and equipment as needed [7].

Core Viewpoint - Gelteq Limited has announced a significant expansion of its U.S. commercial strategy through an exclusive logistics and distribution agreement with Healthy Extracts Inc, aiming to enhance distribution efficiency and revenue potential in North America [1][2][5]. Group 1: Agreement Details - Healthy Extracts is designated as Gelteq's exclusive North American storage, shipping, and fulfillment partner, which is expected to facilitate rapid scaling of Gelteq's proprietary delivery technologies across the U.S. and Canada [2][4]. - The agreement allows Healthy Extracts to manage all product receiving, warehousing, inventory, and order fulfillment from its facility in Henderson, Nevada, optimized for high-volume distribution [3][9]. - Initial products under this agreement are projected for market distribution by Q3 2025, indicating a timeline for operational execution [5]. Group 2: Strategic Implications - The partnership is anticipated to enhance margin efficiencies, drive faster delivery, and create new long-term revenue growth opportunities for both companies [4][9]. - The collaboration is expected to reduce fulfillment costs and unlock high-margin revenue opportunities, aligning both companies' growth plans and innovation strategies [5][9]. - The agreement reflects both companies' commitment to operational excellence and long-term value creation in the health and wellness market [5]. Group 3: Company Background - Gelteq Limited is focused on developing and commercializing white label gel-based delivery solutions across various sectors, including pharmaceuticals and nutraceuticals [6][7]. - Healthy Extracts Inc. specializes in developing and marketing science-based supplements targeting health areas such as brain, heart, and gut health [8].

Group 1 - Gelteq Limited's Sportsgel has signed a three-year sponsorship deal to become the official performance gel for the Professional Pickleball Tour and League of Australia and New Zealand, enhancing its brand visibility in the rapidly growing sport of pickleball [1][2] - The sponsorship grants Gelteq exclusivity for any consumable performance, health, recovery, or other sports-related gels, with branding opportunities at all PPAA and MLPA events, team apparel, and digital platforms [2][3] - The partnership aims to develop tailored, league-branded products that cater specifically to the needs of pickleball athletes, leveraging Gelteq's innovative gel-based delivery technology [2][3] Group 2 - The PPA Tour Australia and Major League Pickleball Australia are committed to expanding the sport of pickleball, featuring elite competition and high-profile owners, which enhances the sport's mainstream appeal [4] - Gelteq is focused on developing and commercializing gel-based delivery solutions across various sectors, including sports nutrition, pharmaceuticals, and nutraceuticals, addressing challenges associated with traditional drug delivery methods [3][4]

Core Insights - Gelteq Limited has announced a three-year sponsorship with the Professional Pickleball Tour Australia (PPAA) and Major League Pickleball Australia (MLPA), marking its entry into the rapidly growing sport of pickleball [1][2] - The sponsorship grants Gelteq exclusivity in providing consumable performance, health, and recovery gels for the leagues, with branding opportunities at events and on team apparel [2][3] - Gelteq's innovative gel-based delivery platform aims to enhance hydration and recovery for athletes, leveraging the expertise of its new Head of Sports Performance [2][3] Company Overview - Gelteq Limited is a biotechnology company based in Melbourne, Australia, focusing on gel-based delivery solutions across various sectors, including pharmaceuticals, nutraceuticals, and sports nutrition [3] - The company addresses challenges associated with traditional drug delivery methods, such as swallowing difficulties and taste issues, through its unique formulation [3] Industry Context - Pickleball is recognized as one of the fastest-growing sports globally, with increasing participation and interest, particularly in Australia and New Zealand [2][4] - The PPAA and MLPA are committed to elevating the sport's profile through elite competition and strategic partnerships, featuring high-profile owners and significant prize money [4]

Core Insights - Gelteq Limited has launched its SportsGel brand, aiming to improve sports performance while addressing taste, mouthfeel, and convenience [1] - The company has secured its first distribution agreement in the Asia-Pacific region with WPIC Marketing and Technologies, focusing on the Chinese market [1][2] - The Chinese sports nutrition market was valued at USD 6.5 billion in 2022 and is projected to grow at an annual rate of 9.1% until 2027 [1] Company Overview - Gelteq Limited is a global biotechnology company headquartered in Melbourne, Australia, specializing in gel-based delivery solutions for various sectors including pharmaceuticals and sports nutrition [3] - The company addresses challenges associated with traditional drug delivery methods, such as difficulty swallowing and taste issues [3] Distribution Partnership - The agreement with WPIC is a strategic move to expand sales in the Asia-Pacific region, with a focus on the Chinese health and fitness market [2] - WPIC has extensive experience in launching global brands in the Asia-Pacific region, which is expected to facilitate the introduction of SportsGel products [4] Product Launch - SportsGel will initially offer sports-specific gels for running and cycling, along with a functional hydration product, with plans for further expansion throughout the year [1] - Gelteq's Head of Sports Performance, Matthew Jones, will oversee the formulations of SportsGel, which will be available for licensing [2]

Company Overview - Gelteq Limited is a global biotechnology company specializing in the formulation, development, and manufacturing of ingestible gel technology [3] - The company is headquartered in Melbourne, Australia and trades on NASDAQ under the ticker GELS [3] - Gelteq focuses on five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition [3] Recent Developments - Gelteq announced the appointment of Matthew Jones as Head of Sports Performance to expand its sports vertical [1] - Jones has over 12 years of experience in elite sports and currently serves as Head of Nutrition for the United Arab Emirates Football Association and as a consultant for the Boston Celtics [2] - The company aims to enhance the adoption of its gel-based delivery platform in the sports sector under Jones's leadership [2] Industry Insights - The sports industry is identified as a key area where Gelteq's unique formulation can significantly improve nutrient delivery compared to traditional methods [2] - The gel-based platform is expected to provide better nutrient and supplement absorption, particularly for athletes [2]

Core Viewpoint - Gelteq Limited has appointed Dr. Paul Wynne as Chief Scientific Officer to enhance its product pipeline and drive growth in its scientific team and business verticals [1][2][3] Company Overview - Gelteq Limited is a global biotechnology company headquartered in Melbourne, Australia, focusing on developing and commercializing gel-based delivery solutions for various sectors including pharmaceuticals, nutraceuticals, and sports nutrition [4] - The company addresses challenges associated with traditional drug delivery methods such as difficulty swallowing and dosage control through its unique formulation [4] Leadership Appointment - Dr. Paul Wynne brings over 35 years of experience in analytical chemistry, drug delivery, and pharmaceutical formulation, previously managing the Medicines Manufacturing Innovation Centre at Monash University [3] - His role will include overseeing product and formulation strategies, intellectual property, academic partnerships, and distribution channels [2][3] Strategic Goals - The appointment of Dr. Wynne is seen as a pivotal moment for Gelteq, aiming to leverage its ingestible gel technology to meet the evolving needs of consumers and patients globally [3] - The company is focused on executing a strategic plan to build long-term value for stakeholders [2]